This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Delaying Progression in ADPKD: Overcoming Barriers to Achieving Optimal Patient Outcomes

Delaying Progression in ADPKD: Overcoming Barriers to Achieving Optimal Patient Outcomes

Format

Webcast

Time to Complete

1 hour

Released

July 31, 2019

Expires

July 31, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Program Description

Clinicians who diagnose and treat autosomal-dominant polycystic kidney disease (ADPKD) are witnessing the dawn of a new era. For the first time, targeted therapies offer the promise of delaying progression in ADPKD—dramatically altering a therapeutic landscape that until recently was exclusively symptom-focused and offered some subgroups only modest delays in progression through rigorous blood-pressure lowering. The management of ADPKD has undergone a paradigm shift following the approval of tolvaptan in April 2018 as a novel therapy to slow progression of cyst development and renal insufficiency in selected patients. In this program, a panel of experts in the management of ADPKD—and 3 patients with ADPKD—share their insights on real-world ADPKD management, including diagnosis, risk assessment, strategies for initiation and monitoring of treatment, and collaboration with a multispecialty, interprofessional team to address the complexities of care, including comorbidities, pain management, and genetic counseling.

Intended Audience

Nephrologists, pediatric nephrologists, internists, pediatricians, family physicians, pain specialists, urologists, cardiologists, and other members of the multidisciplinary care team who may see patients with ADPKD.

Educational Objectives

After completing the activity, the participant should be better able to:

  • Identify patients who are likely to benefit from treatment with tolvaptan or other emerging agents that have been demonstrated in clinical trials to delay progression of ADPKD
  • Monitor changes in renal function and total kidney volume (TKV) using appropriate laboratory and imaging modalities and validated risk-stratification and staging systems to assess disease progression and response to treatment
  • Initiate treatment with tolvaptan or other emerging therapies in accordance with approved indications and mandated monitoring strategies
  • Collaborate with a multispecialty, interprofessional team to address the complexities of care, including comorbidities, pain management, and genetics

Conflict Of Interest Disclosure Policies

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Faculty

Ronald D. Perrone, MD
Scientific Director
Clinical and Translational Research Center
Associate Chief, Division of Nephrology
Professor
Tufts University School of Medicine
Tufts Medical Center
Boston, MA

Dr. Perrone is a consultant for Otsuka America Pharmaceutical, Inc., Palladio Biosciences, Sanofi-Genzyme, and Vertex Pharmaceuticals. He is on the speakers’ bureau for Otsuka America Pharmaceutical, Inc., and receives research grant funds from Kadmon Corporation, Otsuka America Pharmaceutical, Inc., Reata Pharmaceuticals, Inc., Sanofi-Genzyme, and the US Department of Defense.

Simin O. Goral, MD
Director, Polycystic Kidney Disease Clinic
Transplant Nephrology Fellowship Director
Professor of Medicine
Hospital of the University of Pennsylvania
Philadelphia, PA

Dr. Goral receives research grant funds from Astellas Pharma, AstraZeneca, Kadmon Corporation, and Otsuka America Pharmaceutical, Inc.

Osama W. Amro, MD, MS
Swedish Medical Center
National Kidney Foundation Advisory Board
Seattle, WA

Dr. Amro is a consultant and on the speakers’ bureau for Otsuka America Pharmaceutical, Inc.

Pranav S. Garimella, MBBS, MPH, FASN
Assistant Professor of Medicine (Nephrology)
Division of Nephrology and Hypertension
UC San Diego School of Medicine
La Jolla, CA

Dr. Garimella receives research grant funds from Kadmon Corporation.

Paul P. Doghramji, MD, FAAFP (Moderator)
Senior Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA

Dr. Doghramji has no relevant financial relationships to disclose.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Credit Information

Physician Assistant Continuing Education
The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credit for completing this activity.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Otsuka America Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the CME accreditation of this activity, please contact HME at cmequestions@haymarketmedical.com.

If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Instructions

Learners will review the materials on accreditation information, target audience, learning objectives, and disclosure information; complete the pre-test; review the content; and complete the post-test (minimum score of 70% required; learners will only have 3 attempts to pass the post-test) and evaluation to successfully earn credit.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue


Related to this activity